> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 5 Items in Dr. Reddy’s Form FDA-483
- URL: https://www.fdaweb.com/5-items-in-dr-reddys-form-fda-483/
- Published: 2025-10-06T12:00:00.000Z
- Updated: 2026-09-14T15:23:27.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159991

FDA has issued Dr. Reddy's Laboratories a five-item Form FDA-483 after inspecting the firm’s drug substance and drug product manufacturing facility last month in Telangana, India. According to the FDA-483, the agency cited the following:

- The quality unit has not established adequate procedural controls and oversight to ensure the accuracy of environmental monitoring data.
- The firm failed to establish adequate document control procedures and oversight mechanisms to ensure appropriate management of written documents.
- Procedures designed to prevent microbial contamination did not include adequate aseptic techniques.
- Risk assessments for viral cross-contamination control are inadequate to mitigate potential virus cross-contamination risk to drug products.
- Written documents are inadequate to ensure proper documentation and analysis of critical manufacturing operations.

To view the FDA-483, click [here](https://www.fda.gov/media/189059/download?ref=fdaweb.com).